TheraRadar

Briefs tagged "Beleodaq"

1 brief

4-1BB APOLLO-B ATTR amyloidosis ATTR-CM AbbVie Alnylam Amgen Amvuttra Arvinas AstraZeneca Attruby BMS Beleodaq Biogen CAR-T CD40 CNS CRISPR Therapeutics Crohn's disease Eisai Eli Lilly FDA Folotyn GITR HELIOS-B IBD IGF-1R IL-17 IL-23 J&J Johnson & Johnson Keytruda Merck MoonLake Novartis OX40 Onpattro Opdivo Pfizer Regeneron Roche Sandoz Sanofi Spyre TL1A TNF receptor superfamily TTR Takeda UCB Ukoniq Vertex Xencor accelerated approval acoramidis antibody engineering autoimmune bimekizumab biomarkers biosimilars bispecific cardiology cardiovascular clinical trials competitive landscape diagnostics drug development education gene therapy genetics hATTR-PN immunology immunotherapy ixekizumab metabolic oncology ophthalmology patent cliff patisiran precision medicine protein degradation psoriatic arthritis rare disease regulatory secukinumab sonelokimab tafamidis target validation trial design ulcerative colitis vutrisiran
9 min read

Approved Early, Proven Later? What Happens to Cancer Accelerated Approvals

The FDA can put a cancer drug on the market years early, on the promise that proof will follow. We checked all 219 oncology accelerated approvals on the FDA's own lists to see how often a drug with accelerated approval goes on to get full approval.

Of 219 FDA oncology accelerated approvals, 127 (58%) have converted to full approval, 57 (26%) are still waiting and 35 (16%) were withdrawn. Conversion takes a median of 3.3 years, and conversion is not the same as proof: in a 2024 JAMA study, 63% of approvals converted but only 43% showed a clinical benefit. Folotyn has waited since 2009.

Read the full brief
oncologyFDAaccelerated approvaldrug developmentclinical trialsFolotynUkoniqKeytrudaOpdivo

Get the next Brief in your inbox — free

Every drug has multiple stories. Most never get told. One brief every week. No spam.

or just get the emails

Archive at /briefs/. Unsubscribe anytime.